ASCO 2026: Genomics Reveal HRD–Treatment Response Link

• June 5, 2026

Case Report: response of HER2-positive ductal carcinoma in situ to osimertinib with supporting in vitro evidence

• by Shogo Baba, Mami Koketsu, Hajime Kuroda, Megumi Suzuki, Hiroshi Nishihara, Yasutaka Kato, Hiroyuki Kawami, Oi Harada

• May 20, 2026

Redox-metabolic circuits as a central regulator of T cell-based immunotherapy

• by Sarah McPhedran, Tian Zhao, Julian J. Lum

• May 14, 2026

Beating Tissue Failure in Oncology

A patented AI platform trained on NYU Langone research is predicting cancer mutations from haematoxylin and eosin alone — closing the gap for the 25 percent of patients who never reach molecular testing

• by Helen Bristow

• June 4, 2026

• 8 min